Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

We recently compiled a list of the 11 Oversold Blue Chip Stocks to Buy According to Hedge Funds. In this article, we are ...

Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET ...

Regeneron and Sanofi are seeking to expand the use of Dupixent to include more conditions, including chronic obstructive pulmonary disease (COPD), chronic spontaneous Urticaria (CSU) and bullous ...

Sanofi and Regeneron’s blockbuster biologic Dupixent ... asthma and chronic obstructive pulmonary disease (COPD). Sanofi reported in its Q4 2024 results that Dupixent surpassed its €13bn ...

Second, Regeneron's other growth driver, eczema treatment Dupixent -- the rights of which it shares with Sanofi-- is doing great. Fresh off a label expansion in treating COPD last year ...

Though the most important is a new indication in COPD the drug earned last year, there are others. Regeneron and Sanofi are also seeking a label expansion for Dupixent in treating a rare skin ...